Cite
HARVARD Citation
Beer, T. et al. (2015). Autologous dendritic cell immunotherapy (DCVAC/PCa) added to docetaxel chemotherapy in a Phase III trial (viable) in men with advanced (mCRPC) prostate cancer. Journal for immunotherapy of cancer. 3 (2), pp. 1-2. [Online].